Biogen Idec Hemophilia Inc.
Patent owner in reexamination·2 ex parte reexams
Biogen Idec Hemophilia Inc.'s patents have been the subject of 2 USPTO ex parte reexaminations. ExamPat indexes the full prosecution record for each proceeding, including office-action grounds, certificate outcomes, and downstream PTAB and Federal Circuit decisions.
Filings by year
214
Outcome track record
How reexams of this owner's patents resolve: claims confirmed, amended, mixed, or fully canceled.
- Certificate outcome split across every bucket
- Claim-survival rate
Defense metrics
Claim-survival rate, average pendency, and the open/closed split across every reexam of this owner's patents.
- Survival rate of closed proceedings
- Average pendency in months
Challengers & examiners
Which requesters most often challenge this owner's patents, and which examiners decide them.
- Top requesters
- Most frequent examiners
Recent reexaminations (2)
| Control # | Filed | Patent | Title | Requester | Status |
|---|---|---|---|---|---|
| 90/013,296 | Jul 11, 2014 | 7,348,004 | IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS | — | Closed |
| 90/013,242 | Jun 2, 2014 | 7,404,956 | IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS | — | Closed |
See the full reexam picture for Biogen Idec Hemophilia Inc.
Certificate outcomes, pendency, and the parties and examiners behind these cases. Free to sign up.